Daniel A. Driscoll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel A. Driscoll has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Peter K. Sculco
Stavros Niarchos Foundation Complex Joint Reconstruction Center, Adult Reconstruction and Joint Replacement Service, Department of Orthopedic Surgery, Hospital for Special Surgery, 535 E 70th St, New York, NY 10021
4 shared publicationsAjay Premkumar
Adult Reconstruction and Joint Replacement Service, Department of Orthopedic Surgery Hospital for Special Surgery New York New York USA
2 shared publications- Alberto V. Carli
Hospital for Special Surgery, New York, NY
2 shared publications - Christopher G. Anderson
Department of Orthopedic Surgery, Hospital for Special Surgery, New York, NY, USA
2 shared publications - Jeffrey N. Katz
Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts
2 shared publications Jennifer Bido
Orthopedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts; Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
2 shared publications
Latest Publications
- 22 July 2025
- Published by Wiley in Journal of Orthopaedic Research
The Majority of Studies Investigating Biofilm in Orthopedics Score Poorly Using a Standardized Measure of Quality: A Systematic Review
The development of bacterial biofilm is central to the pathogenesis of periprosthetic joint infections following arthroplasty. Consequently, biofilm research in orthopedic surgery has expanded. This study assessed the quality of current orthopedic literature pertaining to the study of biofilm and identified the most commonly used study designs and techniques. A literature search was conducted in PubMed and adapted for Embase and the Cochrane Library. Studies were stratified into in vitro, in vivo (animal), and clinical (human) studies. Studies were included if they evaluated biofilm in an orthopedic context. Clinical studies were included if biofilm was confirmed by a quantification or visualization. Studies were assessed based on study design, biofilm quantification and visualization techniques and quality using the MIABiE score, a standardized tool in appraising biofilm studies. Of 258 studies identified; 65 studies were included after screening. There were 35 studies (50.7%) that evaluated techniques for biofilm treatment, 14 studies (20.3%) evaluated materials for prevention of biofilm formation, and 20 studies (29.0%) investigated descriptive biofilm properties unrelated to treatment or prevention. In vitro studies were most common (62.3%, n = 43). Biofilm quantification techniques were used in 83.0% of studies (n = 57), while only 29 studies (42.0%) used visualization techniques. Most studies (n = 55, 84.6%) were classified as low‐quality based on MIABiE.
- 22 July 2025
- Published by Wiley in Journal of Orthopaedic Research
The Majority of Studies Investigating Biofilm in Orthopedics Score Poorly Using a Standardized Measure of Quality: A Systematic Review
The development of bacterial biofilm is central to the pathogenesis of periprosthetic joint infections following arthroplasty. Consequently, biofilm research in orthopedic surgery has expanded. This study assessed the quality of current orthopedic literature pertaining to the study of biofilm and identified the most commonly used study designs and techniques. A literature search was conducted in PubMed and adapted for Embase and the Cochrane Library. Studies were stratified into in vitro, in vivo (animal), and clinical (human) studies. Studies were included if they evaluated biofilm in an orthopedic context. Clinical studies were included if biofilm was confirmed by a quantification or visualization. Studies were assessed based on study design, biofilm quantification and visualization techniques and quality using the MIABiE score, a standardized tool in appraising biofilm studies. Of 258 studies identified; 65 studies were included after screening. There were 35 studies (50.7%) that evaluated techniques for biofilm treatment, 14 studies (20.3%) evaluated materials for prevention of biofilm formation, and 20 studies (29.0%) investigated descriptive biofilm properties unrelated to treatment or prevention. In vitro studies were most common (62.3%, n = 43). Biofilm quantification techniques were used in 83.0% of studies (n = 57), while only 29 studies (42.0%) used visualization techniques. Most studies (n = 55, 84.6%) were classified as low‐quality based on MIABiE.
- Open Access
- 18 June 2024
- Published by Elsevier in Arthroplasty Today
- Vol. 28, 101398
Radiographic Findings Associated With Mild Hip Dysplasia in 3869 Patients Using a Deep Learning Measurement Tool
- 18 June 2024
- Published by Elsevier in Arthroplasty Today
- Vol. 28, 101398
Open AccessRadiographic Findings Associated With Mild Hip Dysplasia in 3869 Patients Using a Deep Learning Measurement Tool
- 28 February 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (8) , S167-S173.e1
Obesity Severity Does Not Associate With Rate, Timing, or Invasiveness of Early Reinterventions After Total Knee Arthroplasty
- 28 February 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (8) , S167-S173.e1
Obesity Severity Does Not Associate With Rate, Timing, or Invasiveness of Early Reinterventions After Total Knee Arthroplasty
- 18 January 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (7) , 1834-1839
Unexpected Positive Cultures in Hip and Knee Periprosthetic Fractures
- 18 January 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (7) , 1834-1839
Unexpected Positive Cultures in Hip and Knee Periprosthetic Fractures
- 11 January 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (7) , 1752-1757
To Stage or Not to Stage? Comparison of Patient-Reported Outcomes, Complications, and Discharge Disposition After Staged and Simultaneous Bilateral Posterior Total Hip Arthroplasty
- 11 January 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (7) , 1752-1757
To Stage or Not to Stage? Comparison of Patient-Reported Outcomes, Complications, and Discharge Disposition After Staged and Simultaneous Bilateral Posterior Total Hip Arthroplasty
- 21 October 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (4) , 1083-1087.e1
Early Periprosthetic Femur Fractures After Primary Cementless Total Hip Arthroplasty: High Risk of Periprosthetic Joint Infection and Subsequent Reoperation
- 21 October 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (4) , 1083-1087.e1
Early Periprosthetic Femur Fractures After Primary Cementless Total Hip Arthroplasty: High Risk of Periprosthetic Joint Infection and Subsequent Reoperation
- 29 September 2023
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 482 (4) , 688-698
Defining Patient-relevant Thresholds and Change Scores for the HOOS JR and KOOS JR Anchored on the Patient-acceptable Symptom State Question
Background: When evaluating the results of clinical research studies, readers need to know that patients perceive effect sizes, not p values. Knowing the minimum clinically important difference (MCID) and the patient-acceptable symptom state (PASS) threshold for patient-reported outcome measures helps us to ascertain whether our interventions result in improvements that are large enough for patients to care about, and whether our treatments alleviate patient symptoms sufficiently. Prior studies have developed the MCID and PASS threshold for the Hip Disability and Osteoarthritis Outcome Score for Joint Replacement (HOOS JR) and Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) anchored on satisfaction with surgery, but to our knowledge, neither the MCID nor the PASS thresholds for these instruments anchored on a single-item PASS question have been described. Questions/purposes: (1) What are the MCID (defined here as the HOOS/KOOS JR change score associated with achieving PASS) and PASS threshold for the HOOS JR and KOOS JR anchored on patient responses to the single-item PASS instrument? (2) How do patient demographic factors such as age, gender, and BMI correlate with MCID and PASS thresholds using the single-item PASS instrument? Methods: Between July 2020 and September 2021, a total of 10,970 patients underwent one primary unilateral THA or TKA and completed at least one of the three surveys (preoperative HOOS or KOOS JR, 1-year postoperative HOOS or KOOS JR, and 1-year postoperative single-item anchor) at one large, academic medical center. Of those, only patients with data for all three surveys were eligible, leaving 13% (1465 total; 783 THAs and 682 TKAs) for analysis. Despite this low percentage, the overall sample size was large, and there was little difference between completers and noncompleters in terms of demographics or baseline patient-reported outcome measure scores. Patients undergoing bilateral total joint arthroplasty or revision total joint arthroplasty and those without all three surveys at 1 year of follow-up were excluded. A receiver operating characteristic curve analysis, leveraging a 1-year, single-item PASS (that is, “Do you consider that your current state is satisfactory?” with possible answers of “yes” or “no”) as the anchor was then used to establish the MCID and PASS thresholds among the 783 included patients who underwent primary unilateral THA and 682 patients who underwent primary unilateral TKA. We also explored the associations of age at the time of surgery (younger than 65 years or 65 years and older), gender (men or women), BMI (< 30 or ≥ 30 kg/m2), and baseline Patient-Reported Outcome Measure Information System-10 physical and mental component scores (< 50 or ≥ 50) for each of the MCID and PASS thresholds through stratified analyses. Results: For the HOOS JR, the MCID associated with the PASS was 23 (95% CI 18 to 31), with an area under the receiver operating characteristic curve of 0.75, and the PASS threshold was 81 (95% CI 77 to 85), with an area under the receiver operating characteristic curve of 0.81. For the KOOS JR, the MCID was 16 (95% CI 14 to 18), with an area under the receiver operating characteristic curve of 0.75, and the PASS threshold was 71 (95% CI 66 to 73) with an area under the receiver operating characteristic curve of 0.84. Stratified analyses indicated higher change scores and PASS threshold for younger men undergoing THA and higher PASS thresholds for older women undergoing TKA. Conclusion: Here, we demonstrated the utility of a single patient-centered anchor question, raising the question as to whether simply collecting a postoperative PASS is an easier way to measure success than collecting preoperative and postoperative patient-reported outcome measures and then calculating MCIDs and the substantial clinical benefit. Level of Evidence: Level III, therapeutic study.
- 29 September 2023
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 482 (4) , 688-698
Defining Patient-relevant Thresholds and Change Scores for the HOOS JR and KOOS JR Anchored on the Patient-acceptable Symptom State Question
Background: When evaluating the results of clinical research studies, readers need to know that patients perceive effect sizes, not p values. Knowing the minimum clinically important difference (MCID) and the patient-acceptable symptom state (PASS) threshold for patient-reported outcome measures helps us to ascertain whether our interventions result in improvements that are large enough for patients to care about, and whether our treatments alleviate patient symptoms sufficiently. Prior studies have developed the MCID and PASS threshold for the Hip Disability and Osteoarthritis Outcome Score for Joint Replacement (HOOS JR) and Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) anchored on satisfaction with surgery, but to our knowledge, neither the MCID nor the PASS thresholds for these instruments anchored on a single-item PASS question have been described. Questions/purposes: (1) What are the MCID (defined here as the HOOS/KOOS JR change score associated with achieving PASS) and PASS threshold for the HOOS JR and KOOS JR anchored on patient responses to the single-item PASS instrument? (2) How do patient demographic factors such as age, gender, and BMI correlate with MCID and PASS thresholds using the single-item PASS instrument? Methods: Between July 2020 and September 2021, a total of 10,970 patients underwent one primary unilateral THA or TKA and completed at least one of the three surveys (preoperative HOOS or KOOS JR, 1-year postoperative HOOS or KOOS JR, and 1-year postoperative single-item anchor) at one large, academic medical center. Of those, only patients with data for all three surveys were eligible, leaving 13% (1465 total; 783 THAs and 682 TKAs) for analysis. Despite this low percentage, the overall sample size was large, and there was little difference between completers and noncompleters in terms of demographics or baseline patient-reported outcome measure scores. Patients undergoing bilateral total joint arthroplasty or revision total joint arthroplasty and those without all three surveys at 1 year of follow-up were excluded. A receiver operating characteristic curve analysis, leveraging a 1-year, single-item PASS (that is, “Do you consider that your current state is satisfactory?” with possible answers of “yes” or “no”) as the anchor was then used to establish the MCID and PASS thresholds among the 783 included patients who underwent primary unilateral THA and 682 patients who underwent primary unilateral TKA. We also explored the associations of age at the time of surgery (younger than 65 years or 65 years and older), gender (men or women), BMI (< 30 or ≥ 30 kg/m2), and baseline Patient-Reported Outcome Measure Information System-10 physical and mental component scores (< 50 or ≥ 50) for each of the MCID and PASS thresholds through stratified analyses. Results: For the HOOS JR, the MCID associated with the PASS was 23 (95% CI 18 to 31), with an area under the receiver operating characteristic curve of 0.75, and the PASS threshold was 81 (95% CI 77 to 85), with an area under the receiver operating characteristic curve of 0.81. For the KOOS JR, the MCID was 16 (95% CI 14 to 18), with an area under the receiver operating characteristic curve of 0.75, and the PASS threshold was 71 (95% CI 66 to 73) with an area under the receiver operating characteristic curve of 0.84. Stratified analyses indicated higher change scores and PASS threshold for younger men undergoing THA and higher PASS thresholds for older women undergoing TKA. Conclusion: Here, we demonstrated the utility of a single patient-centered anchor question, raising the question as to whether simply collecting a postoperative PASS is an easier way to measure success than collecting preoperative and postoperative patient-reported outcome measures and then calculating MCIDs and the substantial clinical benefit. Level of Evidence: Level III, therapeutic study.
- 23 April 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 38 (7) , S189-S193
Does Acetabular Bone Loss Severity Associate With Patient-Reported Outcome Measures and Reoperation Rate in Revision Total Hip Arthroplasty?
- 23 April 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 38 (7) , S189-S193
Does Acetabular Bone Loss Severity Associate With Patient-Reported Outcome Measures and Reoperation Rate in Revision Total Hip Arthroplasty?
- 12 July 2021
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 40 (5) , 1143-1153
Identifying alternative antibiotics that elute from calcium sulfate beads for treatment of orthopedic infections
There has been increasing interest in the use of a synthetic absorbable calcium sulfate (CaSO4) for local antibiotic delivery in orthopaedic infections. The purpose of this study was to quantify elution kinetics of six antibiotics (amikacin, meropenem, fosfomycin, minocycline, cefazolin, and dalbavancin) from a clinically relevant CaSO4 bead model and compare elution and antimicrobial activity to the current clinical gold standards: vancomycin and tobramycin. Antibiotic‐loaded synthetic CaSO4 beads were immersed in phosphate buffered saline and incubated at 37°C. Eluent was harvested at eight time points over 28 days. Antibiotic concentrations were measured by high performance liquid chromatography to quantify elution rates. CaSO4 beads demonstrated burst release kinetics. Dalbavancin, cefazolin, and minocycline all demonstrated similar elution profiles to vancomycin. Amikacin and meropenem demonstrated favorable elution profiles and durations of above‐minimum inhibitory concentration when compared to tobramycin.Clinical Significance: This study provides important novel data regarding the utility of amikacin, meropenem and dalbavancin as alternative choices to place in CaSO4 carriers when treating orthopaedic infections.
- 12 July 2021
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 40 (5) , 1143-1153
Identifying alternative antibiotics that elute from calcium sulfate beads for treatment of orthopedic infections
There has been increasing interest in the use of a synthetic absorbable calcium sulfate (CaSO4) for local antibiotic delivery in orthopaedic infections. The purpose of this study was to quantify elution kinetics of six antibiotics (amikacin, meropenem, fosfomycin, minocycline, cefazolin, and dalbavancin) from a clinically relevant CaSO4 bead model and compare elution and antimicrobial activity to the current clinical gold standards: vancomycin and tobramycin. Antibiotic‐loaded synthetic CaSO4 beads were immersed in phosphate buffered saline and incubated at 37°C. Eluent was harvested at eight time points over 28 days. Antibiotic concentrations were measured by high performance liquid chromatography to quantify elution rates. CaSO4 beads demonstrated burst release kinetics. Dalbavancin, cefazolin, and minocycline all demonstrated similar elution profiles to vancomycin. Amikacin and meropenem demonstrated favorable elution profiles and durations of above‐minimum inhibitory concentration when compared to tobramycin.Clinical Significance: This study provides important novel data regarding the utility of amikacin, meropenem and dalbavancin as alternative choices to place in CaSO4 carriers when treating orthopaedic infections.